Sarcomatoid Mesothelioma

If your pathology report says sarcomatoid mesothelioma—or you are researching the diagnosis for someone in your family—this page is a place to start. Sarcomatoid is the least common of the three principal mesothelioma histologic subtypes, accounting for about 1 in 10 mesotheliomas overall, although reported proportions vary by anatomical site, study population, and specimen type.^1,2 It is associated with the shortest survival in historical population data and can be especially difficult to distinguish from other spindle-cell tumors and from benign fibrous pleural disease. The word describes how the tumor looks under a microscope; it does not mean the patient has a conventional soft-tissue sarcoma.

Evidence scope. Mesothelioma can arise in the pleura, peritoneum, pericardium, or tunica vaginalis—the membrane around a testicle. The same broad histologic subtypes are recognized across these sites, but the diagnostic, prognostic, and treatment evidence attached to them is not necessarily interchangeable. Most numerical outcomes and clinical-trial results discussed on this page come from diffuse pleural mesothelioma. Peritoneal mesothelioma has a smaller, separate evidence base and different treatment pathways. Primary pericardial mesothelioma and mesothelioma of the tunica vaginalis are exceptionally rare, so the available evidence comes mainly from registries, small series, and case reports. Unless stated otherwise, statistics on this page refer to pleural disease.^2–4

Historical outcomes were poor, but older numbers do not describe the whole modern treatment picture. In a national cancer-registry (SEER) study of 1,183 patients with stage I–III pleural mesothelioma diagnosed from 2004 through 2010, before checkpoint immunotherapy became routine, median overall survival was 4 months for sarcomatoid disease, compared with 10 months for biphasic disease and 14 months for epithelioid disease.⁵ Because the study excluded stage IV disease, its medians are likely higher than they would be for all patients. In CheckMate 743, the pooled non-epithelioid subgroup—which combined sarcomatoid and biphasic tumors—had median overall survival of 18.1 months with nivolumab plus ipilimumab and 8.8 months with chemotherapy.⁶ That result materially changed treatment discussions for non-epithelioid pleural disease, but it is not a sarcomatoid-only median and should not be used as a personal forecast.

You do not need to be an expert in pathology to make sense of your report. Most patients arrive here with a diagnosis they did not choose, a vocabulary they do not speak, and urgent questions that have not been fully answered. The purpose of this page is to help you understand what the report says, what the findings can—and cannot—tell you about treatment and prognosis, and what questions may be worth raising with your medical team.

(Conventional sarcomatoid mesothelioma (left) often shows atypical spindle cells growing into fat or muscle; reactive fibrosis (right) shows bland cells that stay in place. Atypia is not a reliable dividing line on its own: desmoplastic mesothelioma, a sarcomatoid pattern, can be made of bland, sparse cells that look much like scar tissue. Invasion, the overall growth pattern, immunohistochemistry, and tests such as MTAP, BAP1, and CDKN2A usually carry the diagnosis, which is why review by an experienced mesothelioma pathologist matters.⁷)

What sarcomatoid mesothelioma is

The term sarcomatoid describes the appearance and arrangement of tumor cells under a microscope. The cells are usually elongated or spindle-shaped and grow in infiltrating sheets or intersecting fascicles, with cytologic atypia that can range from deceptively mild to highly pleomorphic. Some tumors also contain necrosis, atypical mitoses, or tissue-like elements resembling bone, cartilage, or skeletal muscle.^2,7,9

The name can be confusing. A sarcoma is a cancer arising from connective or supporting tissue. Sarcomatoid mesothelioma is instead a mesothelial cancer whose cells have acquired a spindle-cell appearance. That is why the pathologist must distinguish it not only from epithelioid or biphasic mesothelioma, but also from sarcomatoid carcinoma, synovial sarcoma, other true sarcomas, melanoma, and benign fibrous pleural processes.

At the population level, sarcomatoid histology is associated with more infiltrative growth, lower responsiveness to conventional chemotherapy, and shorter survival than epithelioid histology.^5,9 Those associations do not tell doctors how far one person's cancer has spread or whether a particular treatment will work. Histology does not replace staging, imaging, assessment of lymph nodes, evaluation of overall health, or discussion of the patient's goals.

Sarcomatoid mesothelioma most often arises in the pleura. Contemporary pathology guidance estimates that it accounts for roughly 5% to 15% of pleural mesotheliomas and less than 5% of peritoneal mesotheliomas.⁷ It can also occur at the much rarer pericardial and tunica-vaginalis sites, where the evidence is too sparse to assume that pleural treatment results apply unchanged.

For pleural disease, the histologic diagnosis has important treatment implications. Radical cytoreductive surgery is generally not recommended for sarcomatoid tumors, while systemic treatment—particularly an immunotherapy-containing approach—usually becomes the central anticancer discussion when the patient's condition permits.^6,8 The treatment section later on this page explains the subtype-specific implications without treating histology as the only decision factor.

How sarcomatoid pathology varies

The 2021 WHO classification formally incorporates several morphologic patterns and features within the sarcomatoid category.² These findings can clarify the diagnosis and may add prognostic context, but sarcomatoid pleural mesothelioma does not use the WHO low-grade/high-grade system developed for epithelioid pleural disease.

Transitional morphology

Transitional morphology describes sheet-like growth by elongated but still relatively plump and cohesive tumor cells. The cells can appear intermediate between classic epithelioid and conventional spindle-cell morphology. Historically, such tumors were classified inconsistently. Current WHO and expert diagnostic guidance regard transitional morphology as sarcomatoid because its transcriptomic profile and clinical behavior are closer to sarcomatoid than epithelioid mesothelioma.^2,7

This change can affect the final subtype. Transitional morphology in an otherwise epithelioid tumor may support a biphasic diagnosis, depending on the specimen type and the amount of each component. If a report issued before the 2021 classification mentions “transitional” features, it is reasonable to ask whether the subtype remains the same under current criteria. A re-review does not automatically change the diagnosis; the answer depends on the slides, specimen size, and full morphologic context.

Lymphohistiocytoid and other features

Lymphohistiocytoid morphology consists of tumor cells that resemble histiocytes within a prominent lymphoid background. It is not exclusive to sarcomatoid disease: the main subtype is assigned from the morphology of the non-lymphohistiocytoid component. When this feature occurs in a sarcomatoid tumor, small series have associated it with a relatively more favorable prognosis, but the evidence is limited and it should not be used as a stand-alone prediction.⁷

Other findings that may appear in a sarcomatoid report include:

• Necrosis and atypical mitoses, which support aggressive malignant behavior but do not create a separate WHO grade.
• Pleomorphic cytology, meaning marked variation in cell shape and size.
• Heterologous elements, such as osteosarcomatous, chondrosarcomatous, or rhabdomyosarcomatous differentiation. When extensive, these features make exclusion of a true sarcoma especially important.^7,9

These descriptors add detail to the main diagnosis. They do not create additional principal mesothelioma subtypes.

Molecular and immune markers

BAP1, MTAP, and CDKN2A are best understood as ancillary diagnostic markers. They can help establish that a mesothelial proliferation is malignant after mesothelial lineage has been supported. They do not independently prove that a spindle-cell tumor is mesothelioma, determine stage, or select a standard treatment.^7,10

Marker or finding	What an abnormal result can support	Important limitation in sarcomatoid disease
BAP1 loss by immunohistochemistry	Loss of nuclear BAP1 strongly supports malignancy in a mesothelial proliferation.	BAP1 loss is much less sensitive in sarcomatoid than in epithelioid pleural mesothelioma—reported in only about 20% of sarcomatoid cases in contemporary guidance. Retained BAP1 is therefore common and does not rule out mesothelioma.7
MTAP loss by immunohistochemistry	MTAP loss supports malignancy and often reflects deletion of the nearby 9p21/CDKN2A region. It can be more useful than BAP1 in sarcomatoid tumors.	MTAP is an imperfect surrogate for CDKN2A deletion, and its use as one was validated mainly in pleural mesothelioma. In desmoplastic tumors, scant cytoplasm can make MTAP staining less sensitive, so CDKN2A FISH may remain important.7,10
CDKN2A homozygous deletion by FISH	Homozygous deletion strongly supports a malignant mesothelial proliferation and is more frequent in biphasic and sarcomatoid pleural tumors than in epithelioid tumors.	A negative result does not exclude malignancy. The finding supports malignancy only in the correct morphologic and lineage context.
PD-L1 expression	PD-L1 may provide biological or trial-related information and is sometimes reported before immunotherapy.	PD-L1 is not a diagnostic marker for mesothelioma, is not required for nivolumab plus ipilimumab, and has not been validated as a sufficiently reliable stand-alone predictor of response. Assay results and reported associations with histology and prognosis vary across studies.6,8,11,12

A BAP1 abnormality found only in tumor tissue should be treated as a tumor finding; it does not establish that the alteration was inherited. Germline status requires separate testing, usually on blood or saliva. Current ASCO guidance recommends offering germline genetic testing to all patients with mesothelioma.⁸

An inherited predisposition and asbestos exposure can coexist. Neither a tumor BAP1 result nor a germline result, standing alone, establishes or excludes the role of asbestos in an individual matter. That question requires the exposure history and other case-specific medical and factual evidence.

Desmoplastic mesothelioma

Desmoplastic mesothelioma is a pattern of sarcomatoid mesothelioma characterized by relatively bland, sparse spindle cells arranged haphazardly within dense collagenous stroma. The bland appearance is precisely what makes it difficult: it can resemble fibrous pleuritis, organizing pleuritis, a pleural plaque, or another nonmalignant scar-like process.^2,7

In a definitive resection specimen, desmoplastic morphology must make up at least 50% of the tumor for the formal designation desmoplastic mesothelioma. When the pattern is identified in a smaller biopsy that cannot show the tumor's overall composition, the recommended wording is sarcomatoid mesothelioma with desmoplastic features.^2,7

The diagnosis rests on the overall pattern and, when present, convincing evidence of malignancy. Findings favoring desmoplastic or sarcomatoid mesothelioma over fibrous pleuritis include disorganized or intersecting growth, expansile nodules, abrupt changes in cellularity, tumor necrosis, and invasion into fat, lung, skeletal muscle, or other tissue where mesothelial cells should not normally be present. Broad-spectrum cytokeratin staining can help reveal the distribution of bland tumor cells and highlight invasion. It is not definitive by itself because reactive mesothelial cells and reactive mesothelial stroma can also be keratin-positive.⁷

Ancillary abnormalities such as MTAP loss, BAP1 loss, or CDKN2A homozygous deletion can strongly support malignancy, but negative results do not rule it out. In particular, BAP1 loss has low sensitivity in sarcomatoid disease, and MTAP staining can be difficult to interpret in hypocellular desmoplastic tissue.^7,10

For patients and families, the practical point is not that every diagnosis of fibrous pleuritis is suspect. It is that a benign or indeterminate fibrous result deserves correlation with the imaging, operative findings, symptoms, specimen depth, and clinical course. When the pathology and the rest of the case do not fit together, specialist review of the existing slides and blocks is often the appropriate next step before assuming that another invasive biopsy is necessary.

How sarcomatoid mesothelioma is diagnosed and classified

Diagnosing sarcomatoid mesothelioma is an integrated process. The pathologist evaluates the amount and depth of tissue, the microscopic growth pattern, evidence of invasion, broad-spectrum cytokeratin expression, a panel designed to exclude the relevant carcinomas and spindle-cell tumors, ancillary tests that can support malignancy, and the clinical and imaging findings. No single stain proves the diagnosis, and a negative result on one marker does not automatically exclude it.⁷

The sampling discussion below principally concerns pleural mesothelioma. Tumors arising in the peritoneum, pericardium, or tunica vaginalis may require different biopsy routes and site-specific differential diagnoses.

Tissue sampling

For a patient with suspected pleural mesothelioma who is being evaluated for anticancer treatment, thoracoscopic biopsy is generally preferred when it is medically feasible. It allows the pleural surface to be inspected and multiple samples to be obtained from abnormal areas. Deep, representative tissue is especially valuable when sarcomatoid or desmoplastic disease is suspected because a superficial specimen may contain only bland fibrosis while missing the disorganized growth or invasion beneath it.^7,8

An image-guided core biopsy of an accessible pleural mass or area of thickening can be appropriate when thoracoscopy is not feasible or when imaging provides a safe, representative target. The question is not simply whether a needle or a camera was used; it is whether the specimen contains enough viable, properly handled tissue to answer the relevant diagnostic questions.

Pleural-fluid cytology has particular limitations in sarcomatoid disease because these tumors often shed few diagnostic cells into an effusion. A negative or indeterminate fluid result does not rule out mesothelioma and generally cannot assess the fibrous growth pattern or tissue invasion needed in a desmoplastic differential.⁷

If the initial specimen is inconclusive, the next step is not automatically another procedure. A mesothelioma-specialized pathologist can often review the existing stained slides, unstained slides, and tissue blocks first; request additional stains; and advise whether more tissue is truly needed. When repeat sampling is proposed, the possible diagnostic benefit should be weighed against procedural risk and the importance of not unnecessarily delaying treatment.

Immunohistochemistry: a panel tailored to the differential diagnosis

Immunohistochemistry in sarcomatoid mesothelioma follows a different logic from the classic epithelioid panel. Broad-spectrum cytokeratins are highly sensitive and are often the most useful initial positive finding, but they are not perfectly sensitive or specific. In a series of 326 sarcomatoid mesotheliomas, 93% of the tumors tested (261 of 280) expressed at least one cytokeratin; even after an extensive workup, a small minority of otherwise convincing sarcomatoid mesotheliomas can be cytokeratin-negative.^7,9

A keratin-positive spindle-cell tumor in the pleura is not automatically mesothelioma. Sarcomatoid carcinomas, synovial sarcoma, and some other malignancies can also express cytokeratin. Conversely, reactive mesothelial stromal cells can be keratin-positive, so keratin does not by itself distinguish a benign fibrous pleuritis from desmoplastic mesothelioma. The staining pattern, morphology, invasion, imaging, and the rest of the panel all matter.

Diagnostic question	Commonly considered tests	Important limitation
Are the spindle cells keratin-positive?	Broad-spectrum cytokeratins such as pancytokeratin, AE1/AE3, CAM 5.2, or CK OSCAR	Strongly useful, but a minority of sarcomatoid mesotheliomas are negative and several non-mesothelioma tumors can be positive.
Is mesothelial differentiation supported?	D2-40 and calretinin are among the more useful traditional markers; WT1 and CK5/6 may also be assessed depending on the case.	D2-40 and calretinin are each expressed in only about 50% to 60% of sarcomatoid mesotheliomas, and staining may be focal. Neither is specific: each also stains roughly 20% to 25% of sarcomatoid lung carcinomas. A negative result is common and does not rule out the diagnosis.7
Could this be a sarcomatoid carcinoma?	The panel may include claudin-4, MOC-31, Ber-EP4, TTF-1, Napsin A, p40, or p63, selected for the suspected primary site.	Sarcomatoid carcinomas can lose broad epithelial-marker expression. Negative claudin-4, MOC-31, or Ber-EP4 therefore does not by itself prove mesothelioma.
Could this be another spindle-cell tumor?	Depending on morphology and site, testing may include STAT6, S100 or SOX10, desmin and myogenic markers, PAX8, vascular markers, or SS18-SSX testing for synovial sarcoma.	No fixed panel fits every case. The morphology, imaging, patient history, and suspected alternative diagnosis should determine the tests.

Because both mesothelial and carcinoma markers lose sensitivity in sarcomatoid tumors, an experienced pathologist may need more than one round of testing. A result should be interpreted by where it stains, how strongly and diffusely it stains, whether the positive cells are truly tumor cells, and whether the complete pattern makes biological sense.

Ancillary tests that support malignancy

Once a mesothelial origin is reasonably supported, loss of BAP1 or MTAP by immunohistochemistry and homozygous deletion of CDKN2A by FISH can help distinguish malignant sarcomatoid mesothelioma from a benign mesothelial or fibrous proliferation.^7,10 Their value is asymmetric:

• An abnormal result can provide strong evidence of malignancy in the proper context.
• A normal or negative result does not exclude mesothelioma.
• BAP1 is substantially less sensitive in sarcomatoid tumors than in epithelioid tumors.
• MTAP loss may be more informative in sarcomatoid disease, but staining can be less sensitive in desmoplastic tumors with very little cytoplasm.
• CDKN2A FISH remains particularly useful when morphology is concerning and immunohistochemistry is nondiagnostic.

These tests should not be used as substitutes for establishing lineage or evaluating invasion. MTAP loss, for example, can support malignancy in a mesothelial proliferation but does not distinguish mesothelioma from every other malignant spindle-cell tumor.

SMARCA4-deficient undifferentiated tumor and other mimics

A rare but important modern differential diagnosis is thoracic SMARCA4-deficient undifferentiated tumor, sometimes abbreviated SMARCA4-UT. It is a separate, usually smoking-associated high-grade thoracic malignancy that can involve the mediastinum, lung, and pleural space.¹³ In an undifferentiated or unusual thoracic tumor, loss of SMARCA4/BRG1 expression—often accompanied by loss of SMARCA2/BRM and interpreted with the morphology and broader immunophenotype—can support that diagnosis.¹⁴

SMARCA4 loss is very rare in thoracic mesothelioma, which makes it useful in the appropriate differential, but no single stain should be treated as independently decisive.¹⁵ Not every suspected sarcomatoid mesothelioma requires routine SMARCA4 testing. It is most relevant when the morphology is undifferentiated or rhabdoid, the radiologic distribution is atypical for mesothelioma, the clinical profile suggests another smoking-related thoracic malignancy, or the initial immunohistochemical panel is internally inconsistent.

The broader list of mimics can include sarcomatoid lung carcinoma, metastatic sarcomatoid carcinoma from another organ, synovial sarcoma, solitary fibrous tumor, melanoma, angiosarcoma, myogenic sarcoma, and other spindle-cell neoplasms. That breadth is one reason the diagnosis should not be reduced to “spindle cells plus cytokeratin.”

When expert pathology review is important

A second opinion from a pathologist with substantial mesothelioma and thoracic-pathology experience is particularly valuable when:

• The report uses uncertain language such as “atypical spindle-cell proliferation,” “reactive versus neoplastic,” or “cannot exclude mesothelioma.”
• A biopsy was interpreted as fibrous pleuritis or reactive fibrosis, but the imaging, operative findings, or clinical course remain concerning.
• The tissue is small, superficial, crushed, poorly fixed, or largely fibrotic.
• Broad-spectrum cytokeratin is negative or only focal, or the IHC panel does not form a coherent pattern.
• Sarcomatoid carcinoma, synovial sarcoma, SMARCA4-deficient undifferentiated tumor, or another spindle-cell neoplasm remains in the differential.
• Transitional, desmoplastic, lymphohistiocytoid, pleomorphic, or heterologous features may affect classification.
• An irreversible or high-risk treatment decision is being considered.

A second opinion usually does not require the patient to travel. The original laboratory can send slides and tissue blocks to the consulting center, which then issues a separate report. Additional sampling may still be necessary, particularly when the specimen does not show invasion or contains too little viable tissue, but review of the existing material is often the appropriate first step.

Want help organizing the questions raised by your pathology report? A member of our litigation team—not a medical screener—can review the document with you for case-intake purposes, help identify where terms such as sarcomatoid, desmoplastic, transitional, cytokeratin, BAP1, MTAP, CDKN2A, PD-L1, or SMARCA4 appear, and help you prepare questions for your medical team. We do not diagnose disease or recommend treatment. The conversation is free and creates no obligation.

Call 833-4-ASBESTOS or request a free case review.

What sarcomatoid histology means for treatment

Unless stated otherwise, this section concerns diffuse pleural mesothelioma. Peritoneal mesothelioma follows a smaller, separate treatment literature, and pleural trial results should not automatically be transferred to peritoneal, pericardial, or tunica-vaginalis disease.

Sarcomatoid histology generally narrows the pleural treatment discussion by removing radical cytoreductive surgery from routine consideration and making systemic therapy central. It does not choose a regimen by itself. Disease extent, symptoms, performance status, organ function, autoimmune disease, transplant history, other medical conditions, prior treatment, and the patient's goals remain important.⁸

Radical cytoreductive surgery generally is not recommended

Current ASCO guidance limits cytoreductive surgery to a narrow group of comprehensively staged patients with early-stage epithelioid pleural mesothelioma and favorable characteristics. Sarcomatoid histology therefore generally excludes radical tumor-removing surgery.⁸

That conclusion does not rule out procedures performed primarily to improve comfort or function. Drainage of a pleural effusion, placement of an indwelling pleural catheter, pleurodesis, or another symptom-directed procedure may be appropriate even when pleurectomy/decortication or extrapleural pneumonectomy is not.

Dual checkpoint immunotherapy is generally preferred for untreated non-epithelioid pleural disease

For patients with previously untreated, unresectable non-epithelioid pleural mesothelioma who do not have a contraindication to checkpoint immunotherapy, current ASCO guidance identifies nivolumab plus ipilimumab as the preferred first-line approach.⁸

The pivotal evidence comes from CheckMate 743, in which nivolumab plus ipilimumab produced a large and durable survival advantage over chemotherapy in the pooled non-epithelioid subgroup.^6,16 The exact subgroup figures are discussed in the prognosis section below and in greater treatment detail on the pleural-treatment page.

The result requires three qualifications:

• The trial did not provide a reliable sarcomatoid-only median; sarcomatoid and biphasic tumors were analyzed together.
• The large relative difference partly reflects how poorly chemotherapy performed in the pooled non-epithelioid subgroup. It does not mean sarcomatoid histology has become prognostically favorable.
• A group result cannot predict whether one patient will respond or experience a durable benefit.

ASCO also lists pembrolizumab with platinum-pemetrexed chemotherapy as a first-line option for either epithelioid or non-epithelioid disease. Its first-line recommendation for platinum-pemetrexed chemotherapy, with or without bevacizumab, is framed for epithelioid histology; in non-epithelioid disease, chemotherapy is generally discussed when checkpoint immunotherapy cannot be given or after it.⁸ No randomized trial directly compares all of the available approaches. The reason a patient cannot receive nivolumab plus ipilimumab also matters: a pembrolizumab-containing regimen is not an alternative when the contraindication applies to checkpoint immunotherapy as a class.

What the subtype does—and does not—decide

The practical treatment implication of a sarcomatoid diagnosis is that radical surgery generally leaves the discussion and checkpoint-containing systemic therapy moves toward the center of it. Histology does not establish that immunotherapy will work, make PD-L1 testing mandatory, or eliminate chemotherapy and clinical trials from consideration.

PD-L1 expression has generally been reported more often in sarcomatoid and biphasic tumors than in epithelioid tumors, but it is not a sufficiently reliable stand-alone treatment-selection test. The benefit of nivolumab plus ipilimumab was not limited to PD-L1-positive tumors, and neither PD-L1 nor an exploratory immune-gene signature can guarantee an individual response.^6,8,12

A specialty consultation can be particularly useful when the pathology is uncertain, major medical conditions complicate systemic treatment, or a clinical trial may be available. Much of the day-to-day care can often be delivered locally with a specialty team advising on the overall plan.

For details about drug combinations, dosing, adverse effects, later-line treatment, radiation, tumor treating fields, clinical trials, symptom management, and costs, see our pleural mesothelioma treatment page.

Prognosis and outcomes for sarcomatoid mesothelioma

Sarcomatoid mesothelioma is associated with the shortest survival of the three principal histologic subtypes on average. That is useful population-level information, but it is not an expiration date. Prognosis still depends on the anatomical site, stage, lymph-node involvement, disease burden, the patient's overall condition, the treatments that are medically appropriate, and how the cancer responds.

As explained at the beginning of this page, most of the numerical evidence below concerns diffuse pleural mesothelioma. Peritoneal mesothelioma has a separate evidence base, and the two rarest anatomical sites have too little published information for equally precise estimates.

What historical population data can—and cannot—tell you

In the SEER analysis of 1,183 patients with stage I–III pleural mesothelioma diagnosed from 2004 through 2010, median overall survival was 4 months for sarcomatoid disease, compared with 10 months for biphasic disease and 14 months for epithelioid disease.⁵ Within the sarcomatoid group, the median was 4 months among patients recorded as having cancer-directed surgery and 3 months among those who did not; surgery was not associated with a statistically significant survival improvement after adjustment.⁵

Those data provide historical context, not a contemporary sarcomatoid life-expectancy estimate. The analysis excluded stage IV disease, so its medians are likely higher than they would be for all patients; it included patients with different ages, health conditions, and treatments; it predated routine first-line checkpoint immunotherapy; and it cannot account fully for every selection factor that influenced treatment. The 4-month median should not be presented as the expected outcome for every patient diagnosed today.

Modern trial results are encouraging—but pooled

CheckMate 743 changed expectations for unresectable non-epithelioid pleural mesothelioma. The pooled sarcomatoid-and-biphasic subgroup had median overall survival of 18.1 months with nivolumab plus ipilimumab and 8.8 months with chemotherapy.⁶ At five years, the corresponding survival rates were 12% and 1%.¹⁶

The modern figures should not be converted into a claim that a patient with sarcomatoid disease can expect an 18.1-month median. The study did not report a reliable separate median for sarcomatoid tumors, enrolled patients with previously untreated unresectable pleural disease and an ECOG performance status of 0 or 1, and compared treatment groups rather than describing every patient seen in routine practice. A patient with peritoneal disease, substantial comorbidity, poor functional status, or a clinical situation unlike the trial population may have a different outlook.

There is no formal sarcomatoid WHO grade, but prognosis still varies

The low-grade/high-grade WHO framework discussed on the epithelioid page does not apply to sarcomatoid pleural mesothelioma. That does not mean every sarcomatoid tumor or patient has the same prognosis. Important sources of variation include:

• Anatomical site, stage, lymph nodes, and disease burden. Histology is not a substitute for staging. The amount and distribution of disease affect symptoms, treatment options, and prognosis.
• Performance status, organ function, and other medical conditions. These factors influence both baseline outlook and which treatments can be given safely.
• Treatment received and actual response. Some patients obtain prolonged control from immunotherapy; others do not respond or must stop because of toxicity.
• Diagnostic certainty and specimen representativeness. A small biopsy may underrepresent a biphasic tumor or miss areas with different morphology. A reliable sarcomatoid diagnosis matters before prognosis is discussed.⁷
• Additional pathology features. Limited series suggest that lymphohistiocytoid morphology may be associated with a relatively more favorable course within sarcomatoid disease, but it is not a validated response marker or an individual survival predictor. Desmoplastic mesothelioma remains within the sarcomatoid category; older small series do not justify a precise modern survival estimate for every patient with that pattern.^7,9

A consultation at a center with substantial mesothelioma experience can be useful when the diagnosis is uncertain or the treatment choices are difficult. It should not be described as guaranteeing a better outcome, and it does not necessarily require every infusion or follow-up visit to occur far from home.

Long-term survival

Long-term survival remains uncommon in sarcomatoid mesothelioma, but modern immunotherapy has made multi-year disease control possible for a minority of patients with non-epithelioid pleural disease. The five-year CheckMate 743 result—12% alive with nivolumab plus ipilimumab versus 1% with chemotherapy in the pooled non-epithelioid subgroup—shows a genuine long-term survival tail.¹⁶

It does not reveal how many of those long-term survivors had sarcomatoid rather than biphasic disease, and it cannot identify in advance who will be among them. PD-L1, lymphohistiocytoid morphology, and the exploratory immune signatures studied to date are not sufficiently reliable to make that prediction for one person.

Prognosis information is most useful when it supports concrete planning: discussing treatment goals and risks, controlling breathlessness and pain, considering clinical trials, involving palliative care alongside cancer-directed treatment, preserving quality of life, and addressing work, caregiving, travel, and financial needs. It should not be used to close off medically reasonable options or to tell a family exactly how much time remains.

How sarcomatoid pathology can shape the questions a family asks

The following is a fictional composite created for education. It does not describe a client, promise a treatment result, or predict the outcome of a legal claim.

Douglas, 70, worked for many years as an automobile mechanic and regularly performed brake and clutch work. After progressive shortness of breath and a recurrent left pleural effusion, imaging showed diffuse pleural thickening. A CT-guided core biopsy contained sparse spindle cells in dense fibrous tissue. Broad-spectrum cytokeratin was positive, but the original report stopped at “atypical spindle-cell proliferation; reactive versus malignant process.”

Before another invasive procedure, Douglas's medical team sent the existing slides and tissue block to a pathologist with mesothelioma and thoracic-pathology experience. The reviewer agreed that the specimen was concerning but too superficial to establish invasion confidently. A thoracoscopic biopsy was then obtained from several abnormal pleural areas. The larger specimen showed an infiltrating keratin-positive spindle-cell tumor with loss of MTAP and homozygous CDKN2A deletion. BAP1 staining was retained—a finding that did not exclude sarcomatoid mesothelioma. The integrated diagnosis was sarcomatoid pleural mesothelioma. PD-L1 was also reported, but the pathologist and oncologist explained that it was not a definitive treatment-selection test.

At multidisciplinary review, the team separated radical surgery from symptom-directed procedures. Sarcomatoid histology and the extent of disease made cytoreductive surgery inappropriate, while a tunneled pleural catheter remained an option for recurrent fluid. The medical oncologist discussed nivolumab plus ipilimumab, pembrolizumab with chemotherapy, chemotherapy without immunotherapy, clinical trials, and early palliative-care involvement. The recommendation was based on the complete clinical picture and the pooled non-epithelioid evidence—not on PD-L1 alone. Future decisions would depend on toxicity, imaging, symptoms, and actual treatment response.

At the same time, Douglas's family began reconstructing his work and exposure history. The pathology established the disease diagnosis, but it did not identify which products, companies, suppliers, contractors, or worksites were legally responsible. Counsel investigated which trust claims, civil claims, workers' compensation routes, or disability benefits might apply. The family did not assume that every route was available or that compensation would arrive on a particular schedule.

The point of the example is not that one set of stains produces one treatment or legal result. It is that representative tissue and expert interpretation can resolve a difficult diagnosis, while medical and legal decisions still require separate, case-specific evaluations.

Potential sources of compensation and benefits

A mesothelioma diagnosis may support more than one type of claim or benefit, but no avenue is automatic and the different routes can affect one another. Sarcomatoid histology ordinarily does not open or close a legal channel by itself. Eligibility depends on the diagnosis, exposure evidence, potentially responsible entities, employment or service history, jurisdiction, program rules, and filing deadlines.

• Asbestos bankruptcy trust claims. A claim may be available when the medical and exposure evidence satisfies a particular trust's distribution procedures. Trust requirements, payment percentages, audits, releases, and deadlines vary. How asbestos trust claims work.
• Civil claims against solvent defendants. Depending on the evidence and applicable law, potential defendants may include manufacturers, suppliers, distributors, contractors, or other entities connected to an asbestos-containing product or activity. Product identification, exposure, causation, jurisdiction, and limitations periods all matter. How product-liability claims work.
• Premises or worksite claims. A site owner or another entity that controlled work conditions may be a potential defendant in some jurisdictions and factual settings. Duties, defenses, contractor relationships, and workers' compensation exclusivity rules differ substantially. How premises-liability claims work.
• Veterans, workers' compensation, and disability programs. These programs have separate eligibility rules. The Longshore and Harbor Workers' Compensation Act generally covers maritime workers injured on navigable waters or adjoining areas such as docks and shipyards; FECA is a workers' compensation program for federal employees; Social Security Disability Insurance requires a qualifying disability and sufficient covered work history; and VA disability compensation requires evidence connecting the condition to asbestos exposure during military service.^17–20 Social Security lists pleural, peritoneal, and pericardial mesothelioma, as well as sarcomatoid and desmoplastic mesothelioma, as Compassionate Allowances conditions, which speeds up review of a disability claim but does not change the work-credit or other eligibility rules.²¹ State workers' compensation rules vary. How asbestos disability and benefit claims work.

These routes should be coordinated rather than described as automatically independent. Trust submissions, lawsuits, compensation systems, insurance, Medicare or Medicaid, and benefit programs may involve disclosure duties, liens, offsets, setoffs, releases, exclusivity rules, or reimbursement rights. Filing one claim does not necessarily preserve every other claim, and it does not necessarily eliminate them either.

Sarcomatoid histology can affect the medical evidence, treatment course, damages analysis, and the practical importance of preserving testimony and exposure evidence promptly. It does not create or shorten a legal filing period. Deadlines run under statutes, trust procedures, and program rules—not population survival medians. Expedited procedures may be available in some courts or programs, but they depend on the governing rules and the facts of the case.

References

1. American Cancer Society. Mesothelioma. Last revised February 3, 2026. Accessed October 27, 2026. https://www.cancer.org/cancer/types/malignant-mesothelioma.html
2. Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO Classification of Tumors of the Pleura: advances since the 2015 classification. J Thorac Oncol. 2022;17(5):608-622. doi:10.1016/j.jtho.2021.12.014.
3. Klebe S, Judge M, Brcic L, et al. Mesothelioma in the pleura, pericardium and peritoneum: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology. 2024;84(4):633-645. doi:10.1111/his.15106.
4. Marinaccio A, Consonni D, Mensi C, et al.; ReNaM Working Group. Association between asbestos exposure and pericardial and tunica vaginalis testis malignant mesothelioma: a case-control study and epidemiological remarks. Scand J Work Environ Health. 2020;46(6):609-617. doi:10.5271/sjweh.3895.
5. Meyerhoff RR, Yang CF, Speicher PJ, et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196(1):23-32. doi:10.1016/j.jss.2015.01.043.
6. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. doi:10.1016/S0140-6736(20)32714-8.
7. Husain AN, Chapel DB, Attanoos R, et al. Guidelines for pathologic diagnosis of mesothelioma: 2023 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2024;148(11):1251-1271. doi:10.5858/arpa.2023-0304-RA.
8. Kindler HL, Ismaila N, Bazhenova L, et al. Treatment of pleural mesothelioma: ASCO guideline update. J Clin Oncol. 2025;43(8):1006-1038. doi:10.1200/JCO-24-02425.
9. Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol. 2010;23(3):470-479. doi:10.1038/modpathol.2009.180.
10. Kinoshita Y, Hamasaki M, Yoshimura M, et al. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis. Lung Cancer. 2018;125:198-204. doi:10.1016/j.lungcan.2018.09.019.
11. Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. Hum Pathol. 2019;87:11-17. doi:10.1016/j.humpath.2019.02.001.
12. Brosseau S, Danel C, Scherpereel A, et al. Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the Bio-MAPS cohort. Clin Lung Cancer. 2019;20(5):e564-e575. doi:10.1016/j.cllc.2019.04.010.
13. Rekhtman N, Montecalvo J, Chang JC, et al. SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol. 2020;15(2):231-247. doi:10.1016/j.jtho.2019.10.023.
14. Kezlarian B, Montecalvo J, Bodd FM, et al. Diagnosis of thoracic SMARCA4-deficient undifferentiated tumor in cytology. Cancer Cytopathol. 2023;131(8):526-534. doi:10.1002/cncy.22709.
15. Ahadi MS, Gill AJ. SMARCA4 loss is very rare in thoracic mesothelioma. Am J Surg Pathol. 2019;43(8):1154-1155. doi:10.1097/PAS.0000000000001262.
16. Scherpereel A, Baas P, Nowak AK, et al. Five-year clinical outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for unresectable pleural mesothelioma in CheckMate 743. J Clin Oncol. 2026;44(9):742-749. doi:10.1200/JCO-25-01328. Errata: J Clin Oncol. 2026;44(19):1852, doi:10.1200/JCO-26-01289; and 2026;44(29):2878, doi:10.1200/JCO-26-02181.
17. U.S. Department of Labor, Office of Workers' Compensation Programs. Longshore and Harbor Workers' Compensation Act frequently asked questions. Accessed October 27, 2026. https://www.dol.gov/agencies/owcp/dlhwc/FAQ/lsfaqs
18. U.S. Department of Labor, Office of Workers' Compensation Programs. Federal Employees' Compensation Program. Accessed October 27, 2026. https://www.dol.gov/agencies/owcp/FECA
19. Social Security Administration. Who can get Disability. Accessed October 27, 2026. https://www.ssa.gov/disability/eligibility
20. U.S. Department of Veterans Affairs. Veterans asbestos exposure. Accessed October 27, 2026. https://www.va.gov/disability/eligibility/hazardous-materials-exposure/asbestos/
21. Social Security Administration. Compassionate Allowances (CAL) conditions. Updated August 10, 2026. Accessed October 27, 2026. https://www.ssa.gov/compassionateallowances/conditions.htm
22. Szlosarek PW, Creelan BC, Sarkodie T, et al. Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma: the ATOMIC-Meso randomized clinical trial. JAMA Oncol. 2024;10(4):475-483. doi:10.1001/jamaoncol.2023.6789.
23. Central News Agency (Taiwan). 北極星藥業撤惡性間皮瘤藥證申請 調整美子公司人力 [Polaris Pharmaceuticals withdraws malignant mesothelioma drug license application]. May 25, 2026. Accessed October 29, 2026. https://www.cna.com.tw/news/afe/202605250314.aspx